5TP3

Crystal structure of the RSV-neutralizing single-domain antibody F-VHH-4

  • Classification: IMMUNE SYSTEM
  • Expression System: Homo sapiens

  • Deposited: 2016-10-19 Released: 2017-02-22 
  • Deposition Author(s): Wrapp, D., Gilman, M.S.A., McLellan, J.S.
  • Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences; IWT-Vlaanderen; FWO-Vlaanderen; Ghent University; Inter university Attraction Poles Program; VIB and Mineco 

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.874 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.170 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state.

Rossey, I.Gilman, M.S.Kabeche, S.C.Sedeyn, K.Wrapp, D.Kanekiyo, M.Chen, M.Mas, V.Spitaels, J.Melero, J.A.Graham, B.S.Schepens, B.McLellan, J.S.Saelens, X.

(2017) Nat Commun 8: 14158-14158

  • DOI: 10.1038/ncomms14158
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Human respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children. The RSV fusion protein (F) is highly conserved and is the only viral membrane protein that is essential for infection. The prefusion co ...

    Human respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children. The RSV fusion protein (F) is highly conserved and is the only viral membrane protein that is essential for infection. The prefusion conformation of RSV F is considered the most relevant target for antiviral strategies because it is the fusion-competent form of the protein and the primary target of neutralizing activity present in human serum. Here, we describe two llama-derived single-domain antibodies (VHHs) that have potent RSV-neutralizing activity and bind selectively to prefusion RSV F with picomolar affinity. Crystal structures of these VHHs in complex with prefusion F show that they recognize a conserved cavity formed by two F protomers. In addition, the VHHs prevent RSV replication and lung infiltration of inflammatory monocytes and T cells in RSV-challenged mice. These prefusion F-specific VHHs represent promising antiviral agents against RSV.


    Organizational Affiliation

    Medical Biotechnology Center, VIB, Technologiepark 927, Ghent B-9052, Belgium.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
F-VHH-4
A, B
125N/AMutation(s): 0 
Protein Feature View is not available: No corresponding UniProt sequence found.
Experimental Data & Validation

Experimental Data

Unit Cell:
Length (Å)Angle (°)
a = 47.710α = 90.00
b = 47.770β = 90.00
c = 149.820γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
PHENIXrefinement
Aimlessdata scaling
PDB_EXTRACTdata extraction
iMOSFLMdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical SciencesUnited StatesP20GM113132
National Institutes of Health/National Institute of General Medical SciencesUnited StatesT32GM008704
IWT-VlaanderenBelgiumPh.D. Student Fellowship
FWO-VlaanderenBelgiumPostdoctoral Fellowship
Ghent UniversityBelgiumBOF12/GOA/014
Inter university Attraction Poles ProgramBelgiumIAP7, BELVIR
VIB and MinecoSpainSAF2015-67033-R

Revision History 

  • Version 1.0: 2017-02-22
    Type: Initial release
  • Version 1.1: 2017-03-01
    Type: Database references
  • Version 1.2: 2017-04-26
    Type: Experimental preparation
  • Version 1.3: 2017-09-13
    Type: Author supporting evidence